FDA Approves Expanded Use For Bayer's Prostate Cancer Drug


Crypto Whales Are Loading Up — Are You?

New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.


  • The FDA approved Bayer AG's (OTC:BAYRY) supplemental marketing application for Nubeqa (darolutamide) with docetaxel for metastatic hormone-sensitive prostate cancer (mHSPC).
  • The approval is based on the results of Phase 3 ARASENS trial that demonstrated a reduction in the risk of death by 32% in Nubeqa plus androgen deprivation therapy and docetaxel compared to ADT and docetaxel.
  • Nubeqa plus ADT and docetaxel also resulted in a statistically significant delay in time to pain progression.
  • The recommended darolutamide dose for mHSPC is 600 mg (two 300 mg tablets) taken orally, twice daily, with food until unacceptable toxicity or disease progression. 
  • Docetaxel, 75 mg/m2 intravenously, is administered every three weeks for up to 6 cycles. The first dose of docetaxel should be administered within six weeks after starting darolutamide treatment.
  • In 2019, the FDA approved Nubeqa for non-metastatic castration-resistant prostate cancer (nmCRPC), receiving a concomitant gonadotropin-releasing hormone analog or analog had a bilateral orchiectomy.
  • Price Action: BAYRY shares closed lower by 7.09% at $13.63 on Friday.

Crypto Whales Are Loading Up — Are You?

New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.


ENTER TO WIN $500 IN STOCK OR CRYPTO

Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!

Posted In: BiotechNewsHealth CareFDAGeneralBriefs